Janney Montgomery Scott
ZVRA icon

Janney Montgomery Scott’s Zevra Therapeutics ZVRA Stock Holding History

Janney Montgomery Scott’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.9M Buy
272,194
+35,360
+15% +$393K 0.01% 1107
2026
Q1 		$2.21M Buy
236,834
+33,951
+17% +$306K 0.01% 1220
2025
Q4 		$1.82M Buy
202,883
+19,182
+10% +$181K ﹤0.01% 1384
2025
Q3 		$1.75M Sell
183,701
-72,963
-28% -$732K ﹤0.01% 1390
2025
Q2 		$2.26M Sell
256,664
-23,870
-9% -$194K 0.01% 1151
2025
Q1 		$2.1M Sell
280,534
-16,860
-6% -$134K 0.01% 1139
2024
Q4 		$2.48M Sell
297,394
-7,675
-3% -$65.5K 0.01% 1062
2024
Q3 		$2.12M Sell
305,069
-127,755
-30% -$867K 0.01% 1118
2024
Q2 		$2.12M Sell
432,824
-227,345
-34% -$1.08M 0.01% 1078
2024
Q1 		$3.83M Sell
660,169
-23,262
-3% -$143K 0.01% 856
2023
Q4 		$4.48M Buy
683,431
+9,062
+1% +$42.4K 0.01% 779
2023
Q3 		$3.25M Buy
674,369
+151,599
+29% +$757K 0.01% 836
2023
Q2 		$2.67M Sell
522,770
-5,985
-1% -$32.3K 0.01% 941
2023
Q1 		$2.91M Buy
528,755
+34,725
+7% +$184K 0.01% 825
2022
Q4 		$2.27M Buy
494,030
+14,650
+3% +$74.4K 0.01% 967
2022
Q3 		$2.99M Buy
479,380
+160
+0% +$906 0.01% 801
2022
Q2 		$2.17M Buy
479,220
+129,100
+37% +$589K 0.01% 897
2022
Q1 		$1.76M Buy
350,120
+64,205
+22% +$409K 0.01% 972
2021
Q4 		$2.49M Buy
285,915
+6,475
+2% +$57.8K 0.01% 867
2021
Q3 		$2.61M Buy
279,440
+20,775
+8% +$209K 0.01% 826
2021
Q2 		$3.32M Buy
258,665
+246,365
+2,003% +$2.65M 0.01% 730
2021
Q1 		$113K Buy
+12,300
New +$107K ﹤0.01% 2120
2019
Q3 		– Sell
-841
Closed -$24K – 2157
2019
Q2 		$24K Sell
841
-800
-49% -$20.1K ﹤0.01% 2031
2019
Q1 		$44K Buy
1,641
+88
+6% +$3.24K ﹤0.01% 1975
2018
Q4 		$44K Buy
+1,553
New +$62.8K ﹤0.01% 1914

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Janney Montgomery Scott's ZVRA Position: Q2 2026 in Review

Janney Montgomery Scott increased its Zevra Therapeutics (ZVRA) stake by 15% in Q2 2026, buying an estimated $393K and bringing the position to 272,194 shares worth $3.9M. The position accounts for 0.01% of the portfolio, ranked #1107.

Janney Montgomery Scott first reported a position in ZVRA in Q4 2018 and has held it in 25 quarters since. The position peaked at $4.48M in Q4 2023. 157 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • Janney Montgomery Scott held 272,194 shares of Zevra Therapeutics worth $3.9M as of Q2 2026.
  • Janney Montgomery Scott bought 35,360 Zevra Therapeutics shares in Q2 2026, an estimated $393K.
  • Zevra Therapeutics made up 0.01% of Janney Montgomery Scott's portfolio in Q2 2026, its #1107 holding.
  • Janney Montgomery Scott first reported a position in Zevra Therapeutics in Q4 2018 and has held it in 25 quarters since.
  • Janney Montgomery Scott's Zevra Therapeutics position peaked at $4.48M in Q4 2023.
  • 157 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Janney Montgomery Scott's 13F filing for Q2 2026, filed 5 Aug 2026.